Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress (ECIRRA)
Primary Purpose
Coronary Artery Disease
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Supplement pre CABG
Supplement post CABG
Supplement pre and post CABG
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring insulin resistance, blood glucose, CABG, oxidative stress
Eligibility Criteria
Inclusion Criteria:
- Mean age of 30-70 years old, Having Coronary Artery Disease
- Undergoing coronary artery bypass grafting surgery
Exclusion Criteria:
- Positive history of diabetes mellitus, metabolic, hematological, and immune disorders, renal problem, and cerebrovascular accident
- Taking antioxidant supplements
- Cases for emergency operations
- Ejection Fraction < 30%
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
Supplement pre CABG
Supplement post CABG
Supplement pre and post CABG
Placebo
Arm Description
Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
Consumption of placebo 7 days before surgery and supplement 30 days post surgery
Consumption of the supplement 7 days before and 30 days post surgery
Consumption of placebo 7 days before and 30 days post surgery
Outcomes
Primary Outcome Measures
Serum glucose
It was measured in 5 steps:
1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation
serum insulin
It was measured in 5 steps:
1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation
Hemoglobin A1C
It was measured in 4 steps:
1 week before the operation, Just before the operation, 1 week post operation, 30 days post operation
Insulin Resistance
Calculated by HOMA calculation equation
It was calculated in 5 steps:
1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation
Secondary Outcome Measures
Body Composition changes
It was measured in 4 steps:
1 week before the operation, Just before the operation, 1 week post operation, 30 days post operation
malondialdehyde
It was measured in 5 steps:
1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation
Full Information
NCT ID
NCT02184507
First Posted
July 3, 2014
Last Updated
October 23, 2014
Sponsor
Mohammad Hassan Eftekhari
Collaborators
Shiraz University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT02184507
Brief Title
Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress
Acronym
ECIRRA
Official Title
Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
June 2013 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Mohammad Hassan Eftekhari
Collaborators
Shiraz University of Medical Sciences
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The present study aimed to evaluate the effect of a combination of insulin resistance reducing agents pre and post coronary artery bypass grafting surgery on post-operative blood glucose and oxidative stress regulation.
Detailed Description
The present study aimed to evaluate the effect of a combination of insulin resistance reducing agents pre and post coronary artery bypass grafting surgery on post-operative blood glucose and oxidative stress regulation. The sample size was estimated to be 92 (23 in each group). The participants of the study were selected from the non-diabetic patients scheduled for CABG. The patients were allocated to four groups using balanced block randomization method:
Consumption of the supplement (a 20 gram pack of the supplement daily) 7 days before surgery and placebo (a pack of starch) 30 days post surgery
Consumption of placebo 7 days before surgery and supplement 30 days post surgery
Consumption of the supplement 7 days before and 30 days post surgery
Consumption of placebo 7 days before and 30 days post surgery One week before, before the onset of the surgery, after the surgery, 1 week after and 4 weeks after the operation, blood samples were taken and the levels of hemoglobin A1C, glucose, insulin and malondialdehyde were measured. Also, body composition indices were assessed in four times: one week before the surgery, before the onset of the surgery, 1 week after and 4 weeks after the surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
insulin resistance, blood glucose, CABG, oxidative stress
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
92 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Supplement pre CABG
Arm Type
Experimental
Arm Description
Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
Arm Title
Supplement post CABG
Arm Type
Experimental
Arm Description
Consumption of placebo 7 days before surgery and supplement 30 days post surgery
Arm Title
Supplement pre and post CABG
Arm Type
Experimental
Arm Description
Consumption of the supplement 7 days before and 30 days post surgery
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Consumption of placebo 7 days before and 30 days post surgery
Intervention Type
Dietary Supplement
Intervention Name(s)
Supplement pre CABG
Intervention Description
One sachet of the supplement was consumed daily for 7 days before surgery.
Intervention Type
Dietary Supplement
Intervention Name(s)
Supplement post CABG
Intervention Description
One sachet of the supplement was consumed daily for 30 days after surgery
Intervention Type
Dietary Supplement
Intervention Name(s)
Supplement pre and post CABG
Intervention Description
One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
Primary Outcome Measure Information:
Title
Serum glucose
Description
It was measured in 5 steps:
1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation
Time Frame
37days
Title
serum insulin
Description
It was measured in 5 steps:
1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation
Time Frame
37 days
Title
Hemoglobin A1C
Description
It was measured in 4 steps:
1 week before the operation, Just before the operation, 1 week post operation, 30 days post operation
Time Frame
37 days
Title
Insulin Resistance
Description
Calculated by HOMA calculation equation
It was calculated in 5 steps:
1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation
Time Frame
37 days
Secondary Outcome Measure Information:
Title
Body Composition changes
Description
It was measured in 4 steps:
1 week before the operation, Just before the operation, 1 week post operation, 30 days post operation
Time Frame
37 days
Title
malondialdehyde
Description
It was measured in 5 steps:
1 week before the operation, Just before the operation, After operation, 1 week post operation, 30 days post operation
Time Frame
37 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Mean age of 30-70 years old, Having Coronary Artery Disease
Undergoing coronary artery bypass grafting surgery
Exclusion Criteria:
Positive history of diabetes mellitus, metabolic, hematological, and immune disorders, renal problem, and cerebrovascular accident
Taking antioxidant supplements
Cases for emergency operations
Ejection Fraction < 30%
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohammad Hassan Eftekhari, professor
Organizational Affiliation
Shiraz University of Medical Sciences
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress
We'll reach out to this number within 24 hrs